Recruiting PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT03564340

Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

A Phase 1/2 Study of REGN4018 (Ubamatamab), a MUC16×CD3 Bispecific Antibody, Administered Alone or in Combination With Cemiplimab in Patients With Recurrent Ovarian Cancer or Other Recurrent MUC16+ Cancers

Sponsor: Regeneron Pharmaceuticals

Conditions Endometrial Cancer Low-grade Serous Ovarian Cancer Recurrent Endometrial Cancer Recurrent Fallopian Tube Cancer Recurrent Ovarian Cancer Recurrent Primary Peritoneal Cancer

Interventions Cemiplimab Sarilumab Tocilizumab Ubamatamab

Updated 27 times since 2018 Last updated: Dec 2, 2025 Started: May 21, 2018 Primary completion: Feb 1, 2026 Completion: Jan 31, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Endometrial Cancer and Low-grade Serous Ovarian Cancer, this trial is actively recruiting participants. The trial is conducted by Regeneron Pharmaceuticals and has accumulated 27 data snapshots since 2018. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

27 versions recorded

Jan 2026 — Present [monthly]

Recruiting PHASE1/PHASE2
Dec 2025 — Jan 2026 [monthly]

Recruiting PHASE1/PHASE2
Sep 2025 — Dec 2025 [monthly]

Recruiting PHASE1/PHASE2
Aug 2025 — Sep 2025 [monthly]

Recruiting PHASE1/PHASE2
May 2025 — Aug 2025 [monthly]

Recruiting PHASE1/PHASE2

▶ Show 22 earlier versions

Feb 2025 — May 2025 [monthly]

Recruiting PHASE1/PHASE2
Sep 2024 — Feb 2025 [monthly]

Recruiting PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
May 2024 — Jul 2024 [monthly]

Recruiting PHASE1_PHASE2
Feb 2024 — May 2024 [monthly]

Recruiting PHASE1_PHASE2
Jan 2024 — Feb 2024 [monthly]

Recruiting PHASE1_PHASE2
Dec 2023 — Jan 2024 [monthly]

Recruiting PHASE1_PHASE2
Nov 2023 — Dec 2023 [monthly]

Recruiting PHASE1_PHASE2
Oct 2023 — Nov 2023 [monthly]

Recruiting PHASE1_PHASE2
Jun 2023 — Oct 2023 [monthly]

Recruiting PHASE1_PHASE2
Nov 2022 — Jun 2023 [monthly]

Recruiting PHASE1_PHASE2
Sep 2022 — Nov 2022 [monthly]

Recruiting PHASE1_PHASE2
Apr 2022 — Sep 2022 [monthly]

Recruiting PHASE1_PHASE2
Mar 2022 — Apr 2022 [monthly]

Recruiting PHASE1_PHASE2
Nov 2021 — Mar 2022 [monthly]

Recruiting PHASE1_PHASE2
Feb 2021 — Nov 2021 [monthly]

Recruiting PHASE1_PHASE2
Jan 2021 — Feb 2021 [monthly]

Recruiting PHASE1_PHASE2
Sep 2020 — Jan 2021 [monthly]

Recruiting PHASE1_PHASE2
Apr 2020 — Sep 2020 [monthly]

Recruiting PHASE1_PHASE2
Dec 2018 — Apr 2020 [monthly]

Recruiting PHASE1_PHASE2
Sep 2018 — Dec 2018 [monthly]

Recruiting PHASE1_PHASE2
Jul 2018 — Sep 2018 [monthly]

Recruiting PHASE1_PHASE2

First recorded

May 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Regeneron Pharmaceuticals

Data source: Regeneron Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Badalona, Spain , Barcelona, Spain , Birmingham, United States , Bordeaux, France , Boston, United States , Buffalo, United States , Caen, France , Charleroi, Belgium , Dijon, France , Edegem, Belgium and 29 more locations